The stock's rise snapped a four-day losing streak.

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines ...

Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...

Erste Group upgraded Vertex Pharmaceuticals (VRTX) to Buy from Hold. The firm expects the company to “develop positively in the coming quarters ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

But if not, you'll need to find stocks that hold the potential to pack more punch. The past doesn't predict the future, but ...

Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 ...

Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued to ...

Private foundations providing support, resources, and advocacy for individuals and families affected by rare diseases have ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on ...